Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.


  • Dec 24, 2015 Aiming to Create an Inclusive Society
    Donation to Organizations Committed to Fostering Para-Sports
    [PDF 95KB]
  • Dec 21, 2015 Launch of the Immunosuppressant
    “CellCept® Powder for Oral Suspension 31.8%”
    [PDF 172KB]
  • Dec 14, 2015 Chugai’s ALK Inhibitor “Alecensa®
    Accelerated Approval in Three Months after Priority Review Designation in the US
    [PDF 173KB]
  • Dec 09, 2015 Launch of the ALK Inhibitor “Alecensa® Capsule 150mg”
    -Making Contribution to the Improvement of Convenience of Patients-
    [PDF 149KB]
  • Nov 25, 2015 Organizational and Personnel Changes
    [PDF 214KB]
  • Nov 20, 2015 Anti-Cancer Agent “Xeloda®,”
    Obtained Approval for Additional Indication of
    “Postoperative Adjuvant Chemotherapy for Gastric Cancer”
    [PDF 172KB]
  • Nov 17, 2015 Anti-Cancer Agent “Avastin®,”
    Judgment of the Supreme Court regarding Patent Term Extension
    [PDF 126KB]
  • Nov 09, 2015 Selective SGLT2 Inhibitor “DEBERZA®” Enters a New Phase
    - License Agreement Expanded to Cover US and EU -
    [PDF 153KB]
  • Oct 22, 2015 Chugai to Newly Construct an Antibody API Manufacturing Plant
    Capable of High-Mix Low-Volume Production
    in Preparation for the Consecutive Launch of Innovative Projects
    [PDF 215KB]
  • Oct 22, 2015 F. Hoffmann-La Roche Announces Third Quarter Sales 2015
    [PDF 79KB]
  • Sep 25, 2015 Personnel Changes
    [PDF 111KB]
  • Sep 24, 2015 Contribution of Para-transit Vehicles to Welfare Services
    [PDF 148KB]
  • Sep 18, 2015 NICE Recommends Chugai’s RoACTEMRA® (tocilizumab) as Monotherapy for Treatment of Severe Rheumatoid Arthritis
    [PDF 117KB]
  • Sep 18, 2015 Disclosure of Information on Chugai’s 2014 Corporate Activities
    Based on Transparency Guidelines
    [PDF 111KB]
  • Sep 17, 2015 Anti-Cancer Agent “Avastin®,”
    Application for Approval of Additional Indication of Recurrent/Advanced Cervical Cancer
    [PDF 86KB]
  • Sep 16, 2015 Chugai Selected for the Second Consecutive Year for the Dow Jones Sustainability Asia Pacific Index,
    an Index for Socially Responsible Investment
    [PDF 98KB]
  • Sep 10, 2015 Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®)
    in the UK by Chugai Pharma UK Ltd.
    [PDF 211KB]
  • Sep 09, 2015 Chugai’s ALK Inhibitor “Alectinib,” New Drug Application
    Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer
    in the United States
    [PDF 136KB]
  • Sep 04, 2015 Chugai’s Bispecific Antibody “ACE910” for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA
    [PDF 166KB]
  • Aug 24, 2015 Filing of Public Knowledge-Based Application for Immunosuppressant “CellCept®” for
    Additional Indication of Lupus Nephritis
    [PDF 149KB]
  • Aug 17, 2015 Supplemental Approval of New Formulation of Immunosuppressant,
    “CellCept® Powder for Oral Suspension 31.8%”
    [PDF 186KB]
  • Jul 23, 2015 Organizational and Personnel Changes
    [PDF 146KB]
  • Jul 23, 2015 Relocation of the Tokyo First Branch
    [PDF 119KB]
  • Jul 23, 2015 F. Hoffmann-La Roche Announces Half Year Results 2015
    [PDF 102KB]
  • Jul 14, 2015 Licensing Agreement for Agent Targeting Prevention of Recurrence of Hepatocellular Carcinoma “Peretinoin”
    [PDF 123KB]
  • Jun 25, 2015 Integration and Reorganization of Overseas Subsidiaries
    Aiming to Further Accelerate Overseas Business Activities
    [PDF 247KB]
  • Jun 23, 2015 Positive Interim Data from Phase I/II study of Chugai’s Bispecific Antibody "ACE910" Presented at the ISTH 2015 Congress
    [PDF 176KB]
  • Jun 15, 2015 Japanese Study for ACTEMRA® Showed New Data on the
    Improvement of Symptoms and Safety in Rheumatoid Arthritis at
    EULAR 2015
    [PDF 121KB]
  • May 26, 2015 Guidebook for Employees
    “Working Support Handbook for Cancer Patients”
    [PDF 452KB]
  • May 25, 2015 Filing of New Drug Application for M8010, a Topical Preparation
    Combining an Active Vitamin D3 Derivative and a Corticosteroid
    [PDF 121KB]
  • May 11, 2015 Determination of Terms and Conditions of Stock Options
    (Stock Acquisition Rights)
    [PDF 110KB]
  • May 11, 2015 Relief Efforts Support for the Disaster Area Struck by the Earthquake in Nepal
    [PDF 109KB]
  • May 08, 2015 “Team Chugai” to Take Part in “Relay for Life Japan”
    - Using “3D Adventure Experience” to promote awareness of the early detection and treatment of breast cancer -
    [PDF 2.0MB]
  • Apr 22, 2015 Amendment of Basic Policies Concerning Internal Controls
    [PDF 147KB]
  • Apr 22, 2015 Issuance of Stock Options (Stock Acquisition Rights)
    [PDF 115KB]
  • Apr 22, 2015 F. Hoffmann-La Roche Announces First Quarter Sales 2015
    [PDF 83KB]
  • Apr 03, 2015 Transfer of Marketing Rights for Mercazole® and Propacil®
    from Chugai Pharmaceutical to Aska Pharmaceutical
    [PDF 108KB]
  • Mar 30, 2015 Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate
    Oral Formulation, Bisphosphonate Antiresorptive Agent,
    in Japanese Patients with Osteoporosis Presented
    [PDF 109KB]
  • Mar 27, 2015 Incident Report on Missing Deleterious Substance
    [PDF 151KB]
  • Mar 26, 2015 Approval of Antiviral Drug, Copegus® for Additional Indication
    -First All-Oral Treatment Regimen for Patients with Serogroup 2 HCV in Japan-
    [PDF 152KB]
  • Mar 19, 2015 Chugai selected as a “Nadeshiko Brand,” a company that is
    exceptional in promoting the success of women in the workplace
    — Active diversity measures evaluated by outside agencies —
    [PDF 162KB]
  • Mar 10, 2015 90th Anniversary Commemorative Projects
    Aim at Contributing to Development of Local Communities and
    Medical/Pharmaceutical Sciences
    [PDF 196KB]
  • Mar 02, 2015 Renewal of “Cancer Information Guide,” a Website for Patients
    [PDF 117KB]
  • Mar 02, 2015 Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem® Cell Therapy for Ischemic Stroke in Japan
    [PDF 140KB]
  • Feb 25, 2015 Launch of the Anti-Cancer Agent / BRAF Inhibitor “Zelboraf®
    [PDF 134KB]
  • Feb 10, 2015 New Drug Application Filed for Ibandronate Sodium Hydrate Oral Agent, Bisphosphonate Antiresorptive Agent
    [PDF 94KB]
  • Feb 09, 2015 Chugai Won the Second Prize
    in the 17th NIKKEI Annual Report Awards
    [PDF 163KB]
  • Jan 28, 2015 Chugai to Establish the Organization
    Specializing in Early Clinical Development
    [PDF 123KB]
  • Jan 28, 2015 Personnel Changes
    [PDF 123KB]
  • Jan 28, 2015 Notice of Distribution of Retained Earnings
    [PDF 96KB]
  • Jan 28, 2015 F. Hoffmann-La Roche Announces Financial Results for Fiscal 2014
    [PDF 150KB]
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top